Citadel Advisors’s Gyre Therapeutics GYRE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-3,198
| Closed | -$23.1K | – | 14675 |
|
|
2023
Q3 | $23.1K | Buy |
+3,198
| New | +$21.4K | ﹤0.01% | 12510 |
|
|
2023
Q2 | – | Sell |
-1,057
| Closed | -$3.28K | – | 14695 |
|
|
2023
Q1 | $3.28K | Sell |
1,057
-40,505
| -97% | -$154K | ﹤0.01% | 14054 |
|
|
2022
Q4 | $164K | Buy |
41,562
+33,402
| +409% | +$136K | ﹤0.01% | 10461 |
|
|
2022
Q3 | $31K | Sell |
8,160
-1,957
| -19% | -$24.9K | ﹤0.01% | 11893 |
|
|
2022
Q2 | $135K | Buy |
+10,117
| New | +$67.2K | ﹤0.01% | 11089 |
|
|
2022
Q1 | – | Sell |
-4,202
| Closed | -$20.8K | – | 13978 |
|
|
2021
Q4 | $29K | Sell |
4,202
-4,519
| -52% | -$77.3K | ﹤0.01% | 13485 |
|
|
2021
Q3 | $268K | Buy |
+8,721
| New | +$287K | ﹤0.01% | 11313 |
|
|
2021
Q1 | – | Sell |
-5,909
| Closed | -$270K | – | 13383 |
|
|
2020
Q4 | $280K | Buy |
5,909
+1,786
| +43% | +$77.3K | ﹤0.01% | 9185 |
|
|
2020
Q3 | $133K | Sell |
4,123
-51,059
| -93% | -$2M | ﹤0.01% | 9086 |
|
|
2020
Q2 | $2.43M | Sell |
55,182
-27,597
| -33% | -$1.3M | ﹤0.01% | 4227 |
|
|
2020
Q1 | $2.71M | Buy |
82,779
+32,755
| +65% | +$1.51M | ﹤0.01% | 3636 |
|
|
2019
Q4 | $2.56M | Buy |
50,024
+10,582
| +27% | +$443K | ﹤0.01% | 4030 |
|
|
2019
Q3 | $1.45M | Buy |
39,442
+32,167
| +442% | +$1.73M | ﹤0.01% | 4976 |
|
|
2019
Q2 | $402K | Buy |
7,275
+506
| +7% | +$31.6K | ﹤0.01% | 7141 |
|
|
2019
Q1 | $412K | Sell |
6,769
-3,168
| -32% | -$204K | ﹤0.01% | 7101 |
|
|
2018
Q4 | $588K | Buy |
9,937
+4,095
| +70% | +$302K | ﹤0.01% | 6159 |
|
|
2018
Q3 | $472K | Buy |
5,842
+3,919
| +204% | +$311K | ﹤0.01% | 6793 |
|
|
2018
Q2 | $168K | Buy |
+1,923
| New | +$337K | ﹤0.01% | 8012 |
|
|
2017
Q1 | – | Sell |
-212
| Closed | -$16K | – | 7682 |
|
|
2016
Q4 | $16K | Buy |
212
+49
| +30% | +$4.41K | ﹤0.01% | 7122 |
|
|
2016
Q3 | $22K | Buy |
+163
| New | +$24.6K | ﹤0.01% | 7020 |
|
|
2015
Q2 | – | Sell |
-17
| Closed | -$41K | – | 8856 |
|
|
2015
Q1 | $41K | Sell |
17
-4
| -19% | -$8.26K | ﹤0.01% | 7505 |
|
|
2014
Q4 | $44K | Buy |
21
+11
| +110% | +$21.2K | ﹤0.01% | 7280 |
|
|
2014
Q3 | $20K | Buy |
10
+6
| +150% | +$14.8K | ﹤0.01% | 7413 |
|
|
2014
Q2 | $15K | Buy |
+4
| New | +$13.1K | ﹤0.01% | 7439 |
|
|
2014
Q1 | – | Sell |
-4
| Closed | -$12K | – | 7905 |
|
|
2013
Q4 | $12K | Hold |
4
| – | – | ﹤0.01% | 6662 |
|
|
2013
Q3 | $15K | Sell |
4
-6
| -60% | -$24.1K | ﹤0.01% | 6347 |
|
|
2013
Q2 | $35K | Buy |
+10
| New | +$38K | ﹤0.01% | 5827 |
|
Other funds holding GYRE
TRCT
Citadel Advisors's GYRE Position: Q4 2023 in Review
Citadel Advisors sold out of Gyre Therapeutics (GYRE) in Q4 2023, closing a stake of 3,198 shares — an estimated $23.1K sold.
Citadel Advisors first reported a position in GYRE in Q2 2013 and held it in 27 quarters. The position peaked at $2.71M in Q1 2020. 16 funds tracked by Wall St. Rank hold GYRE as of Q4 2023.
- Citadel Advisors reported no remaining Gyre Therapeutics position as of Q4 2023 after selling out during the quarter.
- Citadel Advisors sold 3,198 Gyre Therapeutics shares in Q4 2023, an estimated $23.1K.
- Citadel Advisors first reported a position in Gyre Therapeutics in Q2 2013 and held it in 27 quarters.
- Citadel Advisors's Gyre Therapeutics position peaked at $2.71M in Q1 2020.
- 16 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q4 2023.
Based on Citadel Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.